Meet Our Team
of Bioanalytical Experts

Dr. Marcelletti has over 35 years of drug development experience, much of which involving regulated bioanalytical lab operations (e.g., GLP, CLIA, CAP). Relevant areas of expertise include use of immunological ligand-binding assays for quantitation of large molecule drugs, peptides, biomarkers, and anti-drug antibodies. Past key positions included Vice President of Large Molecule Bioanalysis (BioAgilytix San Diego) and Senior Lab Director of Immunoanalytical & Cell-based Biotechnology Services (Tandem Labs San Diego, LabCorp Clinical Trials Group).

He held a variety of positions prior to that which involved directing translational medicine operations in oncology, virology, and autoimmunity. Such efforts focused mostly on incorporation of biomarkers into clinical studies as pharmacodynamic and precision medicine tools for diagnosis of diseases and drug development. This includes directing a team of scientists (Avanir Pharmaceuticals, San Diego, CA) that was integral to the invention, development, and FDA approval of Abreva®, a topical antiviral therapeutic for recurrent herpes labialis. Other profile features include 1) Ph.D. from the Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, MI, 2) M.B.A. from the Haworth College of Business at Western Michigan University, Kalamazoo, MI, and 3) >80 scientific publications including primary research journal articles, book chapters, reviews and patents.

Khaled Yamout brings extensive expertise in analytical sciences, quality, and manufacturing to his advisory role. With a strong background in analytical sciences and quality assurance, he has led diverse teams and provided strategic guidance across multiple facets of drug development and manufacturing.

Khaled is an active member of the AMM, contributing to various committees, and serves on the Science & Technology Leadership Committee, offering his expertise to advance the field. He also volunteers with US Pharmacopeia (USP), where he chairs the Expert Panel on mRNA vaccines.

Previously, Khaled served as Senior Director of Analytical Services & Quality Control at TriLink Biotechnologies, where he led the Analytical Sciences Center of Excellence. In this role, he managed method development, validation, product release, and regulatory support for both small and large molecules. His diverse experience spans quality control, research and development, and manufacturing, with a focus on supporting drug substances and products from clinical phases through commercialization.

Khaled’s leadership and technical acumen make him a driving force in advancing quality and innovation in the biopharmaceutical industry.

Dr. Pakritsadang (Petch) Kaewsuya is a highly skilled analytical chemist with extensive expertise in forensic toxicology, drug testing, and environmental analysis. He holds a Ph.D. in Analytical Chemistry with a focus on forensic toxicology from the University of South Carolina. Throughout his career, Dr. Kaewsuya has contributed significantly to the development and validation of analytical methods, particularly in the toxicology field, using cutting-edge techniques like LC/MS/MS, GC/MS, and HPLC.

Dr. Kaewsuya has held leadership roles as Director of Toxicology at multiple diagnostic laboratories, including Quest Diagnostics and Labtech Diagnostics, where he established and managed toxicology departments, optimizing costs and ensuring compliance with regulatory standards such as CLIA, COLA, and CAP. He is an expert in developing and validating testing methods for a variety of substances, including illicit drugs, hormones, and pesticides.

Dr. Kaewsuya’s research has been published in various prestigious journals, and he has presented his work at numerous national and international conferences. Additionally, his academic contributions are supported by his awards, such as the Joseph W. Bouknight Teaching Award, and his membership in the American Association for Clinical Chemistry (AACC). With a diverse background in research, teaching, and laboratory management, Dr. Kaewsuya continues to advance the field of forensic toxicology and environmental analysis.

Dr. Kaewsuya is currently a consultant in various biotech and toxicology laboratories.

Dr. Devanathan obtained his doctoral degree in Chemistry and Biochemistry from Miami University of Ohio. He has pursued research on the discovery of novel biomarkers for metabolic disease, targeted drug development for oncological indications, and development of small molecule therapeutics for neurological diseases/disorders.

With his niche at the intersection of Scientific Research and Entrepreneurship, Dr. Devanathan has not only been involved in Strategic Planning and development of projects around discovering and developing therapeutics, but also in helping build those startups from the ground up both in operational capability as well as in capital raising through NIH’s SBIR/STTR programs.

Besides his professional accomplishments, Dr. Devanathan has been a champion for entrepreneurship and economic empowerment and volunteered his time and expertise to many causes, including The BALSA Group, Arch Grants, Mosaic Project, and Venture café, to name a few. He has also served on the boards of various nonprofit entities. Dr. Devanathan has been recognized in the past by the regional chamber, the Regional business council, and the Business Journal.